The Washington Early Recognition Center specializes in youth psychosis BY KRISTINA SAUERWEIN
Category: Clinical Research
Wash U study aims to find out how divorce affects young children (Links to an external site)
A new study at Washington University seeks to examine how divorce and high parent conflict affect kids ages 4 to 7.
Fighting burnout in health care (Links to an external site)
Researchers at Washington University School of Medicine in St. Louis have launched a research project as part of a new program funded by the Health Resources and Services Administration of the U.S. Department of Health and Human Services to reduce burnout and promote mental health and wellness among those in the health-care workforce.
Wash U researchers are exploring psychedelic drugs — for science (Links to an external site)
Researchers at WashU are studying how psychedelics like psilocybin can be used therapeutically. They discuss its uses — and its limits — during what they say is a “renaissance” of research into the impact of psychedelic drugs.
WashU part of $65 million NIH study of schizophrenia in young people (Links to an external site)
Teens, young adults needed for study aimed at improving early diagnosis
Older people’s resilience during pandemic focus of $9 million grant (Links to an external site)
Research to explore the effects of social isolation on cognitive, emotional health
$6.2 million grant to fund Center for Perioperative Mental Health (Links to an external site)
Researchers to study ways to improve mental health for surgery patients
Laughing gas relieves symptoms in people with treatment-resistant depression (Links to an external site)
Single treatment provides patients with rapid, lasting antidepressant effects
WashU, Pitt awarded $10.7 million for Alzheimer’s disease research (Links to an external site)
Study to look for genetic pathways that lead to formation of plaques, tangles
Finding a possible early treatment for COVID-19 in a 40-year-old antidepressant (Links to an external site)
Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19